Perfusion Cell Culture Patents: Who Leads, Where the Gaps Are 2026
- 79.2% of all activity sits with five assignees. the top five combined account for 84 of 106 records in scope, with a long tail of single-filing entrants below them.
- Filing peaked in 2020 and has not recovered. activity ran from 9 records in 2017 to a high of 16 in 2020, then fell back toward flat by the 2022 midpoint.
- Bioreactor hardware and cell-line engineering dominate claims equally. C12M and C12N each cover 51.9% of the 106 records, while separation and centrifuge classes barely register.
What this landscape covers
Perfusion and intensified cell culture patents concern the hardware, media chemistry and control logic that let a bioreactor run at high viable cell density with continuous or semi-continuous harvest, rather than in a single fixed-volume batch. This search set draws on 106 published records filed between 2015 and mid-2026 that combine perfusion, intensified or high-density culture language with claim terms tied to cell retention devices, media exchange rate, productivity per volume and continuous harvest, restricted to bioreactor and cell-culture IPC classes.
Because publication lags filing by roughly 18 months, the 2025 and 2026 counts in this dataset are necessarily incomplete and should not be read as a real drop-off in activity; the more reliable signal is the shape of the curve through 2022-2023.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 106 records: how filing activity has moved year over year, and which IPC subclasses carry the claims.
Filing activity, 2017-2026
Filings rose from 9 in 2017 to a peak of 16 in 2020, then eased toward a flat midpoint of 1 record in 2022 before the incomplete final years. Read the tail end as reporting lag, not a real contraction.
IPC subclass distribution
C12M (bioreactors and enzyme apparatus) and C12N (microorganisms and genetic engineering) each appear in 51.9% of the 106 records, with C12P (fermentation and enzymatic synthesis) close behind at 34.0%. Measurement and separation classes such as G01J, G01N, B01D and B04B each cover under 3% of records, marking them as thin claim territory relative to the reactor and cell-line core.
Shares are the percentage of the 106 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Perfusion and Intensified Cell Culture with Eureka
This page is one run against one query. Ask Eureka your own question about perfusion and intensified cell culture and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited records
Raman spectroscopy integrated perfusion cell culture system (WuXi Biologics)
The filing describes a bioreactor with dedicated ports for nutrient feed, auto-bleed and continuous harvest via a cell retention system, paired with an in-line Raman analyzer whose probes sit inside the reactor and feed spectral data to a host computer for auto-control of the perfusion process.Filed by WuXi Biologics Ireland Limited, published 2022-09-22 as US20220299370A1.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2013006461A1 | Cholesterol-based media supplementals for cell culture | 70 |
| 2 | US20040259240A1 | Method and apparatus for filtration of bioreactor recombinant proteins | 69 |
| 3 | US20130017577A1 | Methods for enhanced protein production | 51 |
| 4 | US20190169559A1 | Cell retention device and method | 37 |
| 5 | WO2011062926A2 | Methods for enhanced protein production | 23 |
| 6 | US20140363845A1 | Cholesterol-based media supplements for cell culture | 20 |
| 7 | WO2020238918A1 | A raman spectroscopy integrated perfusion cell culture system for monitoring and auto-controlling perfusion c… | 12 |
| 8 | WO2017180814A1 | Cell retention device and method | 11 |
| 9 | WO2021089661A1 | Methods and systems for performing perfusion cell culture | 9 |
| 10 | WO2019072889A1 | Perfusion medium | 8 |
Citation counts favour older filings that have had more time to accumulate references inside this searched corpus; treat them as a signal of influence rather than current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three patterns stand out once the records are grouped by assignee, year and IPC class.
Five assignees hold most of the claim space
The top five assignees combined account for 84 of the 106 records in scope, a concentration that leaves little room for a new entrant to file broad reactor-level claims without running into prior art from an incumbent.
Activity has cooled since 2020
Filing rose steadily to a peak of 16 records in 2020, then fell back to a flat midpoint of 1 record in 2022. Recent-year momentum data shows several leading assignees at 0 filings in the latest year, consistent with a maturing rather than expanding claim base.
Hardware and biology claims run neck and neck
C12M (bioreactor and enzyme apparatus) and C12N (microorganisms and genetic engineering) each cover just over half of the 106 records, meaning neither the physical retention hardware nor the cell-line engineering side is under-claimed relative to the other.
Filing is spread across US, PCT and Europe
The United States leads with 21 records, followed closely by WIPO PCT filings at 20 and European Patent Office filings at 17, with Singapore, Australia and Canada each receiving a smaller but present share.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to perfusion and intensified cell culture, with the prior art for and against each one.
Who is filing, and where the field is still open
The ranked leaders in this dataset cover 30 companies; the field is a small group of large biomanufacturers filing repeatedly, with a long tail of single-filing entrants beneath them.
One assignee sits well ahead of the field
The leading assignee holds 31 records, roughly four times the fifth-place count of 7, indicating a company that has treated perfusion and intensified culture as a core patenting program rather than an occasional filing.
A tight cluster behind the leader
Positions two through five cluster in a narrower band, together with the leader making up 79.2% of all 106 records. Below that band, filing counts drop sharply toward single-digit and single-record positions.
Most ranked companies filed once or twice
By tenth place in the ranking, the count has fallen to a single record, and the pattern continues below that. This is typical of a field defined by a handful of platform holders rather than broad industry-wide adoption of the filing behaviour.
| Assignee | Recent year | YoY |
|---|---|---|
| Boehringer Ingelheim International GmbH | 0 | — |
| Amgen Inc | 0 | -100% |
| Bayer Healthcare LLC | 0 | — |
| E.R. Squibb & Sons, LLC | 0 | — |
| Merck Patent GmbH | 0 | — |
| WuXi Biologics Ireland Limited | 0 | — |
| Medarex, Inc. | 0 | — |
| Ivy Farm Technologies Ltd | 0 | -100% |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, competitive tracking or identifying open claim space.
Check freedom-to-operate against the top five
Since 79.2% of records sit with five assignees, any new reactor-hardware or media-control filing should be checked against that concentrated set before drafting claims.
Run a freedom-to-operate checkTrack momentum shifts among leading filers
Several top assignees show 0 filings in the latest year; watching whether that reflects portfolio maturity or a strategic pause matters for competitive positioning.
Monitor assignee activityExplore the thinner IPC branches
Measurement and separation classes cover under 3% of records each, a possible signal of open claim space around in-line sensing and cell retention hardware.
Explore white space with EurekaCommon questions about perfusion cell culture patents
This dataset contains 106 published records filed between 2015 and mid-2026 that match perfusion, intensified or high-density culture terms combined with claim language around cell retention devices, media exchange rate or continuous harvest. Filing activity peaked at 16 records in 2020 and has since cooled toward flat, though the most recent years are understated because publication typically lags filing by around 18 months. The figure should be read as the scope of this specific search, not a total count of every related filing worldwide.
The ranking covers 30 companies, with the leading assignee holding 31 records against a fifth-place count of 7, meaning the top five together account for 79.2% of all 106 records in scope. That concentration includes major biomanufacturers and contract development organisations that treat perfusion hardware and high-density culture methods as core patent programs. Below the top ten, which together hold 90.6% of records, filing counts drop quickly to single digits, indicating a long tail of occasional filers rather than broad industry-wide activity.
Filing rose from 9 records in 2017 to a peak of 16 in 2020, then fell back toward a flat midpoint of just 1 record by 2022. Recent-year momentum data shows several of the leading assignees recording 0 filings in the latest tracked year. Because publication lags filing by roughly 18 months, the very latest years in any such dataset will always look lower than they eventually turn out to be, so the 2022 flattening is a more reliable signal than the 2025-2026 tail.
The IPC composition shows heavy claim density in bioreactor hardware (C12M, 51.9% of records) and cell-line engineering (C12N, 51.9%), with fermentation methods (C12P, 34.0%) also well covered. By contrast, classes tied to in-line measurement and separation, such as radiation/light measurement, material analysis, filtration and centrifuges, each cover under 3% of the 106 records. That gap suggests process-analytical technology integration and physical separation hardware are comparatively under-claimed relative to the reactor and biology core, though a full freedom-to-operate search would be needed before filing there.
US20220299370A1 is a WuXi Biologics Ireland Limited filing, published 2022-09-22, describing a bioreactor with dedicated feed, auto-bleed and continuous-harvest ports paired with an in-line Raman spectroscopy analyzer that feeds spectral data to a host computer for automated control of the perfusion process. It sits within the broader cluster of cell-retention and continuous-harvest claims that make up a meaningful share of this dataset. Anyone building a perfusion system with integrated real-time spectroscopic control should review this filing's specific claim scope directly rather than relying on the abstract alone.
Research Perfusion and Intensified Cell Culture in depth with Eureka
Go past this page: query the whole perfusion and intensified cell culture corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.